Cornerstone's Lixivaptan Faces Mixed FDA Reviews at CRDAC
By Mari Serebrov
Wednesday, September 12, 2012
Cornerstone Therapeutics Inc. will put its acquisition of Cardiokine Inc. to the test Thursday as it debuts Cardiokine's lone compound, lixivaptan, for the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.